The mouse nrp gene has been found expressed in the embryonic cortical anlage specifically in neocortical layers that are coinciding with the day of emergence of the respective cortical layer during embryonic ontogenetic development. When looking for co-expressing factors for the nrp expressing cells, it becomes obvious that vimentin is the dominant molecule. This intermediate filament is expressed in the embryonic cortex solely in radial glial cells that are providing the scaffold for radial neural migration of excitatory neurons during neocortical development. A subgroup of mouse nrp expressing cells is co-localized with the neuronal specific protein MAP-2. This aforementioned immunocytochemical analysis provides indirect evidence that the NRP gene family is directly involved in "building" embryonic brain architecture by exerting a chemoattractive effect on migrating and developing neuroblasts. This process is followed by final neural differentiation by establishing a functional neural network. At day of birth (P0 mouse), nrp gene expression is ceasing in the cortical plate and emerges in the CA1/CA3 and sub granular zone of the hippocampal formation (active neuronal proliferation zone for neural precursor cells) as well as in the mitral/granular layer of the Bulbus olfactorius ( Figure 1 ). The latter near "nasal" zone expression location could indicate that the nrp gene could well be the elusive "driver" of the rostral neural migration stream which originates from the anterior subventricular zone (SVZa) sending neuroblasts towards the B. olfactorius and replenishing and simultaneously renewing olfactory neurons during the lifetime of a mammal. It also has been recently established that the rostral migration stream is controlled by CXCR4 activation [4] .
Because of the extreme potency of the NRP peptides (characterized 24-mer mouse nrp-derived peptide shows efficacy with EC-50 values in the low femtomolar range within in vitro assay testing of neuronal survival and chemoattraction), this
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Chief Scientist -Managing Director at CuroNZ, New Zealand novel nrp gene and its encoded protein products is so far the most likely published candidate to drive the "construction" of neural sheaths in the mouse neocortex and the brain in general in a chemoattractive manner [1] . In the human genome, we have annotated and experimentally verified at least four locations for nrp gene orthologues, namely 7q31.35 (human CAPS-2), 12q13.1 (human dermcidin), 13q13.2 (predicted human nrp gene, susceptibility locus for petite mal or absence epilepsy), 15q12 (predicted human nrp gene, the identified respective promoter region defines a locus with possible involvement in neocortical thickness variations). The drug development strategy is focused on fragments of the verified RefSeq gene sequence of the CAPS-2 protein because fragments of the dermcidin protein were much less potent than fragments of CAPS-2 in respect of providing neuroprotection and neuroregeneration when tested within relevant neuronal injury in vitro assays.
To the best of our knowledge, the smallest (shortest) possible amino acid sequence that provides complete neural regeneration and neuroprotection in the mammalian CNS derives from the vesicular human protein CAPS-2 (calcium-activator protein for secretion 2) and constitutes the region between amino acids 40-50 representing the length of 11 amino acids. CAPS-2 is a secretory vesicle priming protein with high expression in the cerebellum as well as lung, liver and testis [5, 6] . It is responsible for the secretion of BDNF and NT-3 [7] .
CuroNZ' drug development strategy involved the engineering of two changes into the respective 11-mer sequence (one alanine switch and one incorporation of the non-natural amino acid, alpha-aminoisobutyric acid instead of an alanine residue at position 9). This strategy provides improved physico-chemical shelf life stability for the compound. This drug candidate is named NRP2945 and is now ready for testing in healthy adult volunteers.
NRP2945 has shown a range of pharmacodynamics activities within different animal models of neurodegeneration including optic nerve ligation, MOG-EAE (Myelin Oligodendrocyte Glycoprotein induced Experimental autoimmune Encephalitis), hemi-section spinal cord injury and preclinical relevant models of epilepsy. NRP2945 completely suppressed pentylenetetrazol (PTZ) induced convulsive seizures in male adult Wistar rats [2] . NRP2945 is also capable of suppressing typical absence seizures that are common to the rat strain GAERS when administered as a single subcutaneous bolus. We are currently testing chronic administration paradigms for seizure control in these rats. For the planned clinical phase I/II trial, children with severe refractory epilepsy being categorized as Lennox-Gastaut Syndrome (LGS) will be enrolled to monitor whether NRP2945 will succeed in significantly reducing the seizure load within these young patients who are experiencing a multitude of different types of seizures that are currently only partially controlled by approved adjunctive treatments.
In conclusion, in the future NRPs could provide a viable option for chronic treatment of neuro degenerative diseases by providing a high level of safety with no known off-target effects as well as long-lasting inhibitory network stimulating effects. NRP2945 is diminishing seizure activity during pathological states of global brain circuits. For example it is known that during Status Epilepticus, GABA A receptors are internalized into the cell cytoplasm and therefore are unavailable for extracellular administered and normally effective drugs like benzodiazepines. In contrast, NRP2945 can quickly upregulate protein expression of the synaptic GABA A receptor system as well as GABA and can therefore provide a meaningful inhibitory stimulus during severe states of epilepsy.
